Anti-Xa Levels in Morbidly Obese Patients Using Apixaban or Rivaroxaban, Before and After Bariatric Surgery-Reference-Cited by-同舟云学术

Anti-Xa Levels in Morbidly Obese Patients Using Apixaban or Rivaroxaban, Before and After Bariatric Surgery

Published:2021-11-25 Issue: Volume: Page:
ISSN:0960-8923
Container-title:Obesity Surgery
language:en
Short-container-title:OBES SURG

Author:

Kok Thom^ORCID,de Boer Hans,Witteman Bart,Hovens Marcel,van Luin Matthijs,Monajemi Houshang

Publisher

Springer Science and Business Media LLC

Subject

Nutrition and Dietetics,Endocrinology, Diabetes and Metabolism,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s11695-021-05814-y.pdf

Reference29 articles.

1. Vyas V, Lambiase P. Obesity and atrial fibrillation: epidemiology, pathophysiology and novel therapeutic opportunities. Arrhythm Electrophysiol Rev. 2019;8(1):28–36.

2. Ibáñez L, Sabaté M, Vidal X, et al. Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008–2015): a cross-national drug utilization study. Br J Clin Pharmacol. 2019;85(11):2524–39.

3. Yang G, De Staercke C, Hooper WC. The effects of obesity on venous thromboembolism: a review. Open J Prev Med. 2012;2(4):499–509.

4. Park J, Lee SR, Choi EK, et al. Effectiveness and safety of direct oral anticoagulant for secondary prevention in Asians with atrial fibrillation. J Clin Med. 2019;8(12).

5. Jong L, Koops M, Gout-Zwart JJ, et al. Trends in direct oral anticoagulant (DOAC) use: health benefits and patient preference. Neth J Med. 2018;76:426–30.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unresolved questions on venous thromboembolic disease. Venous thromboembolism (VTE) management in obese patients. Consensus statement of the French Society of Vascular Medicine (SFMV);JMV-Journal de Médecine Vasculaire;2024-09

2. European guidelines on peri-operative venous thromboembolism prophylaxis: first update.;European Journal of Anaesthesiology;2024-07-10

3. Peak plasma anti-Xa direct oral anticoagulant levels after gastrointestinal surgeries: A retrospective cohort;Thrombosis Research;2024-06

4. Pharmacokinetics of single‐dose rivaroxaban under fed state in obese vs. non‐obese subjects: An open‐label controlled clinical trial (RIVOBESE‐PK);Clinical and Translational Science;2024-06

5. Oral Anticoagulants Beyond Warfarin;Annual Review of Pharmacology and Toxicology;2024-01-23